The treatment of breakthrough pain

Pain Medicine

Volumn 8, Issue SUPPL. 1, 2007, Pages

  McCarberg, Bill H ^a  

^a Chronic Pain Management Program   (United States)

Author keywords

Breakthrough Pain; Cancer Related Pain; Chronic Pain; Immediate Release Opioids; Transmucosal Fentanyl

Indexed keywords

ANALGESIC AGENT; CODEINE; FENTANYL; FENTANYL CITRATE; FENTANYL DERIVATIVE; HYDROCODONE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; MORPHINE; MORPHINE SULFATE; NARCOTIC ANALGESIC AGENT; OPIATE; OXYCODONE; PARACETAMOL; PLACEBO; SHORT ACTING DRUG;

ANALGESIA; ANAMNESIS; ANXIETY; BREAKTHROUGH PAIN; CLINICAL STUDY; CLINICAL TRIAL; CONSENSUS; DISABILITY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG WITHDRAWAL; HUMAN; HYDROPHILICITY; LIPOPHILICITY; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; PAIN; PATIENT ASSESSMENT; REVIEW; VESICULAR RASH;

ANALGESICS; ANALGESICS, OPIOID; CHRONIC DISEASE; HUMANS; PAIN; PAIN MEASUREMENT; PHYSICAL THERAPY MODALITIES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES;

EID: 33846344331     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2006.00270.x     Document Type: Review

References (31)

1. Portenoy RK, Hagen NA. Breakthrough pain: Definition, prevalence and characteristics. Pain 1990; 41: 273-81.
2. Bennett D, Burton A, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 1 Assessment. Pharmacy & Therapeutics 2005; 30: 296-301.
3. Abrahm JL. Assessing the patient in pain. In: Abrahm JL, ed. A Physician's Guide to Pain and Symptom Management in Cancer Patients, 2nd edition. Baltimore, MD: Johns Hopkins University Press; 2005: 107-47.
4. Gordon DB, Dahl JL, Miaskowski C, et al. American pain society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. Arch Intern Med 2005; 165: 1574-80.
5. Hanks GWC, Portenoy RK, MacDonald N, O'Neill WM. Difficult pain problems. In: Doyle D, Hanks GWC, MacDonald N, eds. Oxford Textbook of Palliative Medicine, 2nd edition. New York: Oxford University Press; 1998: 454-77.
6. Malmivaara A, Hakkinen U, Aro T, et al. The treatment of acute low back pain-Bed rest, exercises, or ordinary activity? N Engl J Med 1995; 332: 351-5.
7. Waddell G, Feder G, Lewis M. Systematic reviews of bed rest and advice to stay active for acute low back pain. Br J Gen Pract 1997; 47: 647-52.
8. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003; 60: 39-47.
9. Rhiner M, Palos G, Termini M. Managing breakthrough pain: A clinical review with three case studies using oral transmucosal fentanyl citrate. Clin J Oncol Nurs 2004; 8: 507-12.
10. Bennett D, Burton A, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2 Management. Pharmacy & Therapeutics 2005; 30: 354-61.
11. Ripamonti C, Bruera E. Rectal, buccal, and sublingual narcotics for the management of cancer pain. J Palliat Care 1991; 7: 30-5.
12. Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev 2006 Jan 25; (1): CD004311.
13. Mystakidou K, Katsouda E, Parpa E, Tsiatas ML, Vlahos L. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: An overview of its pharmacological and clinical characteristics. Am J Hosp Palliat Care 2005; 22: 228-32.
14. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001; 91: 123-30.
15. Farrar J, Thompson C. Oral Transmucosal Fentanyl Citrate: Efficacy in Neuropathic Pain Patients. Presented at: 24th Annual American Pain Society Scientific Meeting, Boston, MA, March 30-April 2, 2005.
16. Shaiova L, Wallenstein D. Outpatient management of sickle cell pain with chronic opioid pharmacotherapy. J Natl Med Assoc 2004; 96: 984-6.
17. Lennernäs B, Hedner T, Holmberg M, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: A new approach to treatment of incident pain. Br J Clin Pharmacol 2005; 59: 249-53.
18. Durfee S, Messina J, Khankari R. Fentanyl effervescent buccal tablets. Am J Drug Deliv 2006; 4: 1-5.
19. Darwish M, Tempero K, Kirby M, Thompson J. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600pg and dose proportionality of FEBT 270 to 1,300 microg: A single-dose, randomized, open-label, three-period study in healthy adult volunteers. Clin Ther 2006; 28: 715-24.
20. Portenoy R, Taylor D, Messina J, Tremmel L. A Randomized, Placebo-Controlled Study of Fentanyl Effervescent Buccal Tablets for Breakthrough Pain in Opioid-Treated Patients with Cancer. Presented at: American Academy of Pain Medicine's Annual Meeting, San Diego, CA, February 22-25, 2006.
21. Rauck R, Segal T, Taylor D, Messina J. Long-Term Safety And Tolerability of Fentanyl Effervescent Buccal Tablets: Interim Analysis in Patients with Cancer-Related Breakthrough Pain. Presented at: American Academy of Pain Medicine's Annual Meeting, San Diego, CA, February 22-25, 2006.
22. Hale M, Webster L, Peppin J, Messina J. Open-Label Study of Fentanyl Effervescent Buccal Tablets in Patients with Chronic Pain and Breakthrough Pain: Interim Safety And Tolerability Results. Presented at: American Academy of Pain Medicine's Annual Meeting, San Diego, CA, February 22-25, 2006.
23. Davis MP, Walsh D, Lagman R, LeGrand SB. Controversies in pharmacotherapy of pain management. Lancet Oncol 2005; 6: 696-704.
24. Abrahm JL. Nonpharmacologic strategies for pain and symptom management. In: Abrahm JL, ed. A Physician's Guide to Pain and Symptom Management in Cancer Patients, 2nd edition. Baltimore, MD: Johns Hopkins University Press 2005: 279-316.
25. Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain: Consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002; 94: 832-9.
26. Gordon DB. Oral transmucosal fentanyl citrate for cancer breakthrough pain: A review. Oncol Nurs Forum 2006; 33: 257-64.
27. Collins SL, Faura CC, Moore RA, McQuay HJ. Peak plasma concentrations after oral morphine: A systematic review. J Pain Symptom Manage 1998; 16: 388-402.
28. Poyhia R, Seppala T, Olkkola KT, Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992; 33: 617-21.
29. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man, 2nd edition. Davis, CA: Biomedical Publications; 1982.
30. Felder C, Uehlinger C, Baumann P, Powell K, Eap CB. Oral and intravenous methadone use: Some clinical and pharmacokinetic aspects. Drug Alcohol Depend 1999; 55: 137-43.
31. Fine PG, Streisand JB. A review of oral transmucosal fentanyl citrate: Potent, rapid and noninvasive opioid analgesia. J Palliat Med 1998; 1: 55-63.